Researchers are rapidly focused on retatrutide compounds , a novel dual agonist targeting both GLP-1 and GIP receptors. This unique strategy appears to offer significant potential for physique management and related metabolic concerns. Early medical studies have demonstrated promising results, implying a potential evolution in how we address obesi